{"nct_id":"NCT01243762","title":"A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)","status":"TERMINATED","status_verified_date":"2018-07","start_date":"2010-11-22","start_date_type":"ACTUAL","primary_completion_date":"2012-12-04","primary_completion_date_type":"ACTUAL","completion_date":"2013-03-25","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["MRK"]}